ALLO vs. AUPH, CVAC, MLYS, PAHC, RCUS, WVE, SNDX, COLL, ELVN, and SYRE
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Wave Life Sciences (WVE), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs. Its Competitors
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aurinia Pharmaceuticals presently has a consensus target price of $11.50, suggesting a potential upside of 42.15%. Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 482.38%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Aurinia Pharmaceuticals.
In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 8 mentions for Allogene Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Allogene Therapeutics' score of 1.08 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
Allogene Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Allogene Therapeutics' return on equity.
Aurinia Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Aurinia Pharmaceuticals received 287 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 66.21% of users gave Allogene Therapeutics an outperform vote.
Summary
Aurinia Pharmaceuticals beats Allogene Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ALLO Stock Free ALLO Stock Alerts